Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of Lingze tablet for benign prostatic hyperplasia
ChiCTR2100045691Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Lingze in benign prostatic hyperplasia (BPH), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoints: International Prostate Symptom Score, Quality of Life score and 1 more. Started May 2021; status: recruiting.
02
Drugs
Lingze
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR2100045691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045691.